Review decision - November 2011
Review of NICE Technology Appraisal Guidance no. 158; Oseltamivir, amantadine and zanamivir for the prophylaxis of influenza (including a review of TA67)
The Institute proposed that the guidance should be transferred to the ‘static guidance list’ for Technology Appraisals and that the NICE TA158 webpage should include a hyperlink to the current Chief Medical Officer advice on influenza.
During consultation, the majority of comments received by the Institute agreed with the proposal put forward. After consideration of all of the comments (attached as appendix A), the Institute’s Guidance Executive has decided to proceed with the proposal.
This page was last updated: 24 November 2011